Other substances

mAb 1D2

A human monoclonal antibody against SARS-CoV-2 Spike protein.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

mAb 1D2 is human monoclonal antibody against SARS-CoV-2 Spike protein identified among the antibodies produced in convalescent patients' B cells (Chi et al, 2020). It blocks the interaction between S1 domain and human high-density lipoprotein with possible implication for SARS-CoV-2 infectivity (Wei et al., 2020).

 

Supporting references

Link Tested on Impact factor Notes Publication date
HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry
Spike protein In vitro Antibody 		in vitro biophysical assay; Huh-7 cells

The antibody blocked the interaction between the S1 domain of SARS-CoV-2 Spike protein and human high-density lipoprotein (HDL), which was shown to significantly reduce HDL-enhanced SARS-CoV-2 infection in vitro.

 Nov/26/2020
Export (.csv)